Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Status:
RECRUITING
Trial end date:
2027-05-30
Target enrollment:
Participant gender:
Summary
This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.